Teva Reports Results of Ajovy (fremanezumab) in Two P-II/III Clinical Studies for the Treatment of Migraine in Japan

 Teva Reports Results of Ajovy (fremanezumab) in Two P-II/III Clinical Studies for the Treatment of Migraine in Japan

Teva Reports Results of Ajovy (fremanezumab) in Two P-II/III Clinical Studies for the Treatment of Migraine in Japan

Shots:

  • The two P-II/III studies involve assessing of Ajovy vs PBO in patients with chronic and episodic migraine respectively
  • The two P-II/III studies resulted in meeting its 1EPs and 2EPs and is well tolerated. The results will serve as a basis to file MAA for PMDA’s approval in Japan
  • Ajovy is the first and only anti-CGRP therapy, approved in the US and EU, indicated for the preventive treatment of migraine offering both quarterly and monthly dosing options, currently in development in Japan by Otsuka, under 2017 licensed agreement signed b/w the companies

Click here ­to­ read full press release/ article | Ref: Teva | Image: Teva

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post